www.bioscience.co.uk
Sales & Support: +44 (0)1223 316 855

Fresh human leukopaks

Cambridge Bioscience has a close collaboration with Research Donors, a London-based clinic, dedicated to the collection of fresh human leukopaks for research purposes.

Our leukapheresis service provides researchers with fresh leukopaks containing 10 billion total nucleated cells on average from a single donor, with delivery available on the same or next day after collection (location dependent).

Collections are tailored to each researchers' specific needs, so the choice of volume, shipment temperature and blood group is yours. Leukopaks contain highly concentrated peripheral blood mononuclear cells (PBMC) which are ideal for applications including immunology and cell therapy (e.g. CAR-T) research, toxicology studies and high-throughput drug screening.

Research Donors is an HTA licensed, ISO 9001 2015 certified establishment, as well as participating in the UK NEQAS QA scheme. Fresh human leukopak

Benefits of using our fresh leukopaks
• 10 billion total nucleated cells per donor on average
• Same day or overnight delivery available (location dependent)
• Specific donor criteria requests accommodated
• High-viability PBMC with minimal degradation
• Fresh leukopak collection available 4 days per week
• Comprehensive donor information provided, including full blood counts
• HTA-licensed, ISO 9001 2015 certified facility
• Samples fully consented including for genetic analysis, animal models and commercial research purposes
• Large donor pool
• Available in full, half or quarter bag sizes
• Donors pre-screened for HIV, HBV, HCV, Syphilis, HTLV I and HTLV II

Search our fresh human leukopaks products

See what researchers say about our leukapheresis service

Leukopak validation data

pre-freeze phenotype leukopak

Post thaw phenotype leukopak

Left: Flow cytometry was used to assess the expression of CD3, TCR α/β, TCR Vδ1, TCR Vδ2, CD14 and CD56 within PBMC freshly-isolated from leukoapheresates from three healthy donors. The data for αβT cells (CD3+TCR α/β +), Vδ1 yδT cells (CD3+TCR Vδ1+), Vδ2 yδT cells (CD3+TCR Vδ2+), monocytes (CD3-CD14+) and NK cells (CD3-CD56) is shown as mean percentage + SEM. Right: Flow cytometry was used to assess the expression of CD3, TCR α/β, TCR Vδ1, TCR Vδ2, CD14 and CD56 within PBMC immediately post cryorecovery in 10% DMSO from leukoapheresates from three healthy donors. The data for αβT cells (CD3+TCR α/β +), Vδ1 yδT cells (CD3+TCR Vδ1+), Vδ2 yδT cells (CD3+TCR Vδ2+), monocytes (CD3-CD14+) and NK cells (CD3-CD56) is shown as mean percentage + SEM.
Data courtesy of Jonathan Fisher et al, UCL Great Ormond Street Institute of Child Health, London, UK.

post thaw viability and recovery leukopak

PBMCs were cryopreserved in 10% DMSO and post-thaw viability was determined via trypan blue exclusion. Cell counts pre- and post-cryopreservation were used to calculate the percentage recovery. Mean percentage + SEM and individual values are shown for PBMCs from leukoapheresates from three healthy donors. Mean cell recovery after cryopreservation was 67% for leukapheresate samples.
Data courtesy of Jonathan Fisher et al, UCL Great Ormond Street Institute of Child Health, London, UK.

Transduction Impact on viability

Cryopreserved PBMC from leukoapheresates from three healthy donors were thawed, rested overnight in complete media (RPMI1640 supplemented with L- Glutamine and 10% FCS) and stimulated with a translationally relevant T cell expansion cocktail; specifically, PBMC received a single does of TCR stimulus post-thaw and were cultured in complete media containing 100 IU/mL IL-2. The expansion was supplemented with fresh IL-2 containing media every 2-3 days. T cell viability was assessed using flow cytometry after 12 days of stimulation for cell viability. Day 12 overall cell viability was consistently >60% for all samples, with marginal impact on post-transduction. Mean percentage + SEM and individual values are shown for n=3.
Data courtesy of Jonathan Fisher et al, UCL Great Ormond Street Institute of Child Health, London, UK.

Transduction Efficiency

Cryopreserved PBMC from donor matched leukapheresates from three healthy donors were thawed, rested overnight in complete media (RPMI1640 supplemented with L- Glutamine and 10% FCS) and stimulated with a translationally relevant T cell expansion cocktail; specifically, PBMC received a single does of TCR stimulus post-thaw and were cultured in complete media containing 100 IU/mL IL-2. The expansion was supplemented with fresh IL-2 containing media every 2-3 days. T cell transducibility was assessed by viral transduction using a translationally-relevant lentiviral vector and protocol. T cell transduction efficiency was assessed on day 12 of expansion. T cells of donor matched leukapheresate origin were highly and efficiently transducible with a lentiviral multiplicity of infection of 4, with a mean efficiency of >90%. Mean percentage + SEM and individual values are shown for n=3.
Data courtesy of Jonathan Fisher et al, UCL Great Ormond Street Institute of Child Health, London, UK.

Transduction impact on Proliferation

Cryopreserved PBMC from three healthy donors were thawed, rested overnight in complete media (RPMI1640 supplemented with L- Glutamine and 10% FCS) and stimulated with a translationally relevant T cell expansion cocktail; specifically, PBMC received a single does of TCR stimulus post-thaw and were cultured in complete media containing 100 IU/mL IL-2. The expansion was supplemented with fresh IL-2 containing media every 2-3 days. T cell expansion was assessed using flow cytometry and counting beads after 12 days of stimulation for cell viability. Non-transduced leukapheresate T cells expanded at a mean >180-fold, whilst transduced T cells expanded to a similar extent at a mean 100-fold. Mean percentage + SEM and individual values are shown for n=3.
Data courtesy of Jonathan Fisher et al, UCL Great Ormond Street Institute of Child Health, London, UK.

Leukapheresis process
With the wider use of cellular immune therapies, there is an increased demand from researchers for highly concentrated PBMC from a single individual. The traditional method of isolating PBMC from standard blood donations is limited by the maximum volume of blood that can be collected per donor (500 ml) and typically results in 1 to 2 million PMBC per ml of blood. Leukapheresis is the process by which a large number of total nucleated cells are separated from the blood of a single donor, resulting in a high concentration of PBMC, such as lymphocytes (T cells, B cells, and NK cells), monocytes and dendritic cells.

Leukapheresis process - fresh human leukopak

1. Whole blood is collected from the donor via intravenous tube in one arm

2. Whole blood passes through a Spectra Optia® apheresis machine, which separates white blood cells from the blood

3. The white blood cells are collected in a leukopak for storage

4. The unused blood components are safely returned to the donor via intravenous tube in the other arm

 

Contact our blood specialists
To request a quote or find out more, please contact our blood specialists

These products are for research use only and not for any diagnostic or therapeutic use. It is your responsibility to ensure that you have necessary licensing and ethics approvals in place for the use and storage of any human tissue related material supplied by Cambridge Bioscience.

Spectra Optia is a registered trademark of Terumo BCT, Inc